In 2018, cannabis-based medical products (CBMPs) were rescheduled to Schedule 2 in the UK. This allows these products to be prescribed at the discretion of a specialist doctor who is on the GMC Specialist Register. As these products are unlicensed, the prescribing clinician retains responsibility for any negative effects resulting in the use of these prescribed products. Based on GMC guidance, prescribing of CBMPs should only be considered in specific circumstances. Because of this, Elios Clinics require patients to have trialled 2 conventional treatment options and have been seen by a specialist clinician in secondary care for their condition. Conventional treatments vary depending on condition, but may include oral pharmacological therapies, injected therapies and talking therapies. We may therefore need to ask for evidence from patients showing that they meet this eligibility criteria prior to booking their first consultation.
Eligibility Criteria:
- Trialed 2 conventional treatment options
- Have been seen by a specialist clinician in secondary care for their condition.
You can complete the eligibility assessment form here: https://www.eliosclinics.com/assessment/